Headlines about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.5622133891327 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news articles that may have effected Accern’s rankings:

A number of research firms have commented on TTOO. HC Wainwright set a $8.00 target price on T2 Biosystems and gave the company a “buy” rating in a research report on Monday, February 12th. Goldman Sachs Group began coverage on T2 Biosystems in a research report on Monday, January 29th. They issued a “neutral” rating and a $5.20 target price on the stock. Finally, Zacks Investment Research downgraded T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $5.56.

T2 Biosystems (TTOO) traded up $1.28 during trading hours on Friday, reaching $6.36. The company’s stock had a trading volume of 1,550,000 shares, compared to its average volume of 237,779. T2 Biosystems has a 12 month low of $2.50 and a 12 month high of $6.99. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.40 and a quick ratio of 5.28. The stock has a market capitalization of $227.85, a P/E ratio of -3.35 and a beta of 1.49.

ILLEGAL ACTIVITY NOTICE: “T2 Biosystems (TTOO) Given News Impact Score of 0.17” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/03/04/t2-biosystems-ttoo-given-news-impact-score-of-0-17.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.